×
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
NASDAQ:SRNE

Sorrento Therapeutics Stock Forecast, Price & News

$2.02
-0.01 (-0.49%)
(As of 06/28/2022 11:04 AM ET)
Add
Compare
Today's Range
$1.99
$2.04
50-Day Range
$1.24
$2.28
52-Week Range
$1.15
$11.07
Volume
94,376 shs
Average Volume
12.33 million shs
Market Capitalization
$785.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
30 days | 90 days | 365 days | Advanced Chart

Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Stock Forecast (MarketRank)

Overall MarketRank

2.16 out of 5 stars

Medical Sector

421st out of 1,436 stocks

Biological Products, Except Diagnostic Industry

68th out of 217 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Sorrento Therapeutics logo

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

SRNE Stock News Headlines

Sorrento Therapeutics (NASDAQ:SRNE) Stock Price Up 10.4%
Sorrento Therapeutics (NASDAQ:SRNE) Shares Gap Down to $1.63
Sorrento Therapeutics (NASDAQ:SRNE) Shares Gap Up to $1.59
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
Employees
799
Year Founded
N/A

Company Calendar

Today
6/28/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+890.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-428.33 million
Net Margins
-826.96%
Pretax Margin
-883.87%

Debt

Sales & Book Value

Annual Sales
$52.90 million
Book Value
$0.26 per share

Miscellaneous

Free Float
376,111,000
Market Cap
$785.68 million
Optionable
Optionable
Beta
2.43














Sorrento Therapeutics Frequently Asked Questions

Should I buy or sell Sorrento Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics
or view top-rated stocks.

What is Sorrento Therapeutics' stock price forecast for 2022?

1 brokers have issued 1 year price objectives for Sorrento Therapeutics' stock. Their SRNE stock forecasts range from $20.00 to $20.00. On average, they expect Sorrento Therapeutics' share price to reach $20.00 in the next year. This suggests a possible upside of 895.0% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Sorrento Therapeutics' stock price performed in 2022?

Sorrento Therapeutics' stock was trading at $4.65 at the beginning of the year. Since then, SRNE shares have decreased by 56.8% and is now trading at $2.01.
View the best growth stocks for 2022 here
.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Sorrento Therapeutics
.

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji Ph.D., Chairman, Pres & CEO (Age 58, Pay $1.69M)
  • Ms. Elizabeth Adkins Czerepak M.B.A., Exec. VP, CFO & Chief Bus. Officer (Age 66, Pay $8.12k)
  • Mr. Brian Cooley, Sr. VP of Corp. Communications & Investor Relations
  • Mr. William J. Farley B.Sc., VP of Sales & Bus. Devel. (Age 66)
  • Dr. Michael A. Royal, SVP & Chief Medical Officer (Age 68)
  • Dr. Alexis Nahama D.V.M., Sr. VP of Neurotherapeutics BU
  • Dr. Mark R. Brunswick, Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D., Sr. VP of Commercial Operations
  • Dr. Robert D. Allen Ph.D., Sr. VP of R&D
  • Dr. Xiao Xu M.D., Pres of ACEA

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (8.73%), BlackRock Inc. (5.67%), Vanguard Group Inc. (4.09%), JPMorgan Chase & Co. (0.85%), Northern Trust Corp (0.72%) and UBS Group AG (0.64%). Company insiders that own Sorrento Therapeutics stock include Henry Ji, Kim Janda and Robin L Smith.
View institutional ownership trends for Sorrento Therapeutics
.

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., JPMorgan Chase & Co., Royal Bank of Canada, Walleye Trading LLC, Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., Jane Street Group LLC, and Northern Trust Corp.
View insider buying and selling activity for Sorrento Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Bank of America Corp DE, Goldman Sachs Group Inc., GSA Capital Partners LLP, Qube Research & Technologies Ltd, BlackRock Inc., and Victory Capital Management Inc..
View insider buying and selling activity for Sorrento Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $2.01.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $781.79 million and generates $52.90 million in revenue each year.

How many employees does Sorrento Therapeutics have?

Sorrento Therapeutics employs 799 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at [email protected], or via fax at 858-210-3759.

This page (NASDAQ:SRNE) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.